Back to results
US 2021/0230247 A1Published application
Lilrb1-based chimeric antigen receptor
AssigneeA2 Biotherapeutics, Inc.
InventorsCarl Alexander KAMB, Agnes E. HAMBURGER, Breanna DIANDRETH, Mark E. DARIS, Kiran DESHMUKH
Life of this patent
Estimating the term…
Abstract
Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
Claims27
A chimeric antigen receptor comprising a polypeptide comprising:
- a) an antigen binding domain;
- b) an LILRB1 hinge domain or functional fragment or variant thereof;
- c) a transmembrane domain;
- and
- d) an LILRB1 intracellular domain comprising at least one immunoreceptor tyrosine-based inhibitory motif (ITIM) selected from the group consisting of NLYAAV (SEQ ID NO:
- 8), VTYAEV (SEQ ID NO:
- 9), VTYAQL (SEQ ID NO:
- 10), and SIYATL (SEQ ID NO:
- 11).
6 more elements
The immune cell of 25, further comprising an activator receptor.
Dependencies are inferred from the claim text.